研究单位：[1]Taizhou Hanzhong biomedical co. LTD[2]Cancer Hospital, Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[3]Affiliated Hospital of Hebei University,Baoding,China[4]Beijing Yuhe Combination of Chinese Traditional and Western Medicine Recovery Hospital,Beijing,China[5]The First Affiliated Hospital of Bengbu Medical College,Bengbu,China[6]Hunan Cancer Hospital,Changsha,China[7]Xiangya Hospital, Central South University,Changsha,China[8]Heping Hospital Affiliated to Changzhi Medical College,Changzhi,China[9]Fujian Cancer Hospital,Fuzhou,China[10]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,China[11]Zhejiang Cancer Hospital,Hangzhou,China[12]The affiliated Cancer Hospital of Harbin Medical University,Harbin,China[13]Anhui Provincial Cancer Hospital,Hefei,China[14]Shandong Cancer Hospital,Jinan,China[15]Jiangsu Provincial People's Hospital,Nanjing,China[16]Guangxi Medical University Cancer Hospital,Nanning,China[17]Fudan University Cancer Center,Shanghai,China[18]Liaoning Cancer Hospital,Shenyang,China[19]The First Hospital of China Medical University,Shenyang,China[20]Peking university shenzhen hospital,Shenzhen,China[21]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China[22]The Second Affiliated Hospital of Soochow University,Suzhou,China[23]Shanxi Cancer Hospital,Taiyuan,China[24]Tianjin Cancer Hospital,Tianjin,China[25]Tianjin People's Hospital,Tianjin,China[26]Hubei Cancer Hospital,Wuhan,China[27]Wuhan Central Hospital,Wuhan,China[28]The First Affiliated Hospital of Xi'an Jiaotong University,Xian,China[29]The First Affiliated Hospital of Xinxiang Medical College,Xinxiang,China[30]Henan Cancer Hospital,Zhengzhou,China[31]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China
研究目的：
In this study, patients of advanced gastric adenocarcinoma with failed first-line chemotherapy-line or advanced mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced solid carcinoma will be treated with HX008 combined with irinotecan and HX008 monotherapy There will be two cohorts in this study: Cohort 1 and Cohort 2. For Cohort 1, advanced gastric adenocarcinoma with failed first-line chemotherapy-line cancer participants, who had failed or were unable to tolerate first line chemotherapy with platinum-based or fluorouracil regimens. For Cohort 2, advanced solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.
